ERBB2-Mutated Metastatic Lung Adenocarcinoma With Progression Across Multiple Regimens
This lung cancer diagnosis at a glance
- Subtype
- Adenocarcinoma
- Biomarkers
- ERBB2 V777delinsVGSP mutation
- Sex
- male
- Treatment
- chemotherapy and targeted therapy
- Outcome
- Setback / Progression
Treatment course, step by step
- Carboplatin and pemetrexed were given for 2 months before progression.
- Cisplatin plus docetaxel followed for 3 months and produced stable disease.
- Erlotinib was given for 4 months before progression.
- Gemcitabine was given for 2 months before progression.
- Afatinib was then given for 2 months before further progression.
What happened, in summary
A man with metastatic lung adenocarcinoma had an ERBB2 V777delinsVGSP mutation and a limited smoking history. Carboplatin and pemetrexed were given for 2 months, but the cancer progressed. He then received cisplatin plus docetaxel for 3 months, which produced stable disease. Erlotinib followed for 4 months, and the cancer progressed. Gemcitabine was then given for 2 months and the disease again progressed. Afatinib was used next for 2 months, but progression continued. Overall, only a temporary period of disease stability was achieved amid several chemotherapy and HER2-directed treatment attempts.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Afatinib for Lung Cancer 37 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer